Relypsa Inc (RLYP) 31.98 $RLYP Galenica announc
Post# of 273257
Posted On: 09/04/2016 9:04:07 AM
Relypsa Inc (RLYP) 31.98 $RLYP
Galenica announces Expiration of Cash Tender Offer for Shares of Common Stock of Relypsa
GlobeNewswire - Thu Sep 01, 12:08AM CDT
Galenica Group today announced that its tender offer to purchase the outstanding shares of common stock of Relypsa, Inc., (NASDAQ: RLYP) at USD 32.00 per share, net to the seller in cash, without interest and less any applicable withholding taxes, expired at 12:00 midnight New York time, at the end of the day on Wednesday, August 31, 2016. The tender offer was effected by Galenica's indirect wholly owned subsidiary, Vifor Pharma USA Inc.
RLYP: 31.98 (-0.01)
Relypsa Announces Phase 4 Study Shows Veltassa(R) Demonstrated Similar Efficacy and Safety Whether Given With or Without Food in Patients with Hyperkalemia
GlobeNewswire - Tue Aug 30, 3:05PM CDT
Relypsa, Inc. (NASDAQ:RLYP), a biopharmaceutical company, today announced that the Phase 4 TOURMALINE study, which compared the efficacy and safety of Veltassa (patiromer) for oral suspension given with or without food for the treatment of hyperkalemia, met its primary endpoint. Results showed no statistically significant difference in the percent of patients achieving either week 3 or week 4 serum potassium in the target range (3.8 - 5.0 mEq/L) between the group taking Veltassa with food and that taking it without. Adverse events with Veltassa in this study were consistent with previous clinical trials. Data from the TOURMALINE study will be submitted for presentation at a future medical meeting and shared with the U.S. Food and Drug Administration (FDA).
RLYP: 31.98 (-0.01)
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Relypsa, Inc. (RLYP)
GlobeNewswire - Mon Aug 15, 6:00PM CDT
Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Relypsa, Inc. ("Relypsa" or the "Company"
(Nasdaq:RLYP) in the United States District Court for the Northern District of California on behalf of current stock holders of Relypsa, seeking to pursue remedies under the Securities Exchange Act of 1934 (the "Exchange Act".
RLYP: 31.98 (-0.01)
Galenica commences Tender Offer for Relypsa
GlobeNewswire - Thu Aug 04, 12:08AM CDT
Galenica Group today announced that its indirect wholly owned subsidiary, Vifor Pharma USA Inc., is commencing today its previously announced tender offer for any and all outstanding shares of common stock of Relypsa, Inc. (NASDAQ: RLYP) at a price of USD 32.00 per share in cash, without interest and less applicable withholding taxes. The tender offer is being made in connection with the Agreement and Plan of Merger, dated July 20, 2016, among Galenica Ltd., Vifor Pharma USA Inc. and Relypsa, Inc.
RLYP: 31.98 (-0.01)
Biotechnology Stocks Under Review - Eleven Biotherapeutics, Relypsa, Galena Biopharma, and Amgen
PR Newswire - Mon Jun 20, 7:25AM CDT
On Friday, June 17, 2016, the NASDAQ Composite ended the trading session at 4,800.34, down 0.92%; the Dow Jones Industrial Average edged 0.33% lower, to finish at 17,675.16; and the S&P 500 closed at 2,071.22, down 0.33%. However, five out of nine sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Eleven Biotherapeutics Inc. (NASDAQ: EBIO), Relypsa Inc. (NASDAQ: RLYP), Galena Biopharma Inc. (NASDAQ: GALE), and Amgen Inc. (NASDAQ: AMGN). Learn more about these stocks by accessing their free trade alerts at:
EBIO: 4.84 (-0.05), RLYP: 31.98 (-0.01), AMGN: 169.77 (-0.36), GALE: 0.40 (unch)
Relypsa Announces New Employment Inducement Grants
GlobeNewswire - Mon Jun 06, 3:15PM CDT
Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on June 1, 2016, the compensation committee of the company's board of directors granted 2 new employees options to purchase an aggregate of 6,250 shares of the company's common stock with a per share exercise price of $19.86, the closing trading price on the grant date, and 3,125 restricted stock units. The stock options and restricted stock units were granted pursuant to the Relypsa, Inc. 2014 Employment Commencement Incentive Plan, which was approved by the company's board of directors in June 2014 under Rule 5635(c)(4) of the Nasdaq Global Select Market for equity grants to induce new employees to enter into employment with the company.
RLYP: 31.98 (-0.01)
Relypsa (RLYP) Shows Strength: Stock Moves 8.8% Higher
Zacks Equity Research - Zacks Investment Research - Mon May 30, 7:15AM CDT
Relypsa, Inc. (RLYP) shares rose almost 9% in the last trading session.
RLYP: 31.98 (-0.01), AZN: 33.31 (+0.71)
Relypsa Up on CRL for AstraZeneca Hyperkalemia Drug
Zacks Equity Research - Zacks Investment Research - Mon May 30, 6:30AM CDT
Shares of Relypsa, Inc. (RLYP) gained after AstraZeneca (AZN) received a CRL regarding its NDA for its hyperkalemia candidate, ZS-9.
RLYP: 31.98 (-0.01), PFE: 34.77 (+0.09), AZN: 33.31 (+0.71), BMY: 56.35 (-0.41)
Relypsa Submits Supplemental New Drug Application to FDA Requesting Label Changes for Veltassa Based on Phase 1 Drug-Drug Interaction Studies
GlobeNewswire - Wed May 25, 3:15PM CDT
Relypsa, Inc. (NASDAQ:RLYP), a biopharmaceutical company, today announced that the company has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) requesting label changes for Veltassa(patiromer) for oral suspension based on results of 12 Phase 1 drug-drug interaction studies in healthy volunteers.
RLYP: 31.98 (-0.01)
Data from New Analyses of Studies with Veltassa(R) Presented at 53rd European Renal Association Congress
GlobeNewswire - Sun May 22, 10:00AM CDT
Relypsa, Inc. (NASDAQ:RLYP), a biopharmaceutical company, today announced that data from new analyses of studies with Veltassa(patiromer) for oral suspension were presented at the 53 Congress of the European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) in Vienna.
RLYP: 31.98 (-0.01)
Why Under Armour, Relypsa, and HollyFrontier Slumped Today
Dan Caplinger, The Motley Fool - Motley Fool - Wed May 04, 5:33PM CDT
Image: Under Armour. Wednesday put continued pressure on the stock market, and investors appeared to focus on ongoing pressure in the energy sector and fears about global macroeconomic conditions in pushing major market benchmarks lower on the day....
UA: 38.56 (-1.19), RLYP: 31.98 (-0.01), HFC: 24.68 (+0.03)
Relypsa reports 1Q loss
Automated Insights - Wed May 04, 5:02PM CDT
REDWOOD CITY, Calif. (AP) _ Relypsa Inc. (RLYP) on Wednesday reported a loss of $54.8 million in its first quarter.
RLYP: 31.98 (-0.01)
Relypsa Reports First Quarter 2016 Financial Results
GlobeNewswire - Wed May 04, 3:07PM CDT
Relypsa Management to Host Conference Call/Webcast this Afternoon at 5:00 p.m. ET/2:00 p.m. PT
RLYP: 31.98 (-0.01)
Why Relypsa Inc.'s Shares Are Crashing 16% Today
Todd Campbell, The Motley Fool - Motley Fool - Wed May 04, 11:01AM CDT
SOURCE: RELYPSA, INC. What: After closing an offering of $150 million in senior-secured loans yesterday, shares of Relypsa are trading lower by 15.9% at 11:00 a.m. EST Wednesday morning. So what: The company has borrowed $150 million in...
RLYP: 31.98 (-0.01)
Relypsa Announces $150 Million Debt Financing
GlobeNewswire - Tue May 03, 3:15PM CDT
Relypsa, Inc. (NASDAQ:RLYP), a biopharmaceutical company, today announced the closing of $150 million in aggregate principal amount of senior secured term loans (the "Loans", led by funds advised by Athyrium Capital Management and joined by HealthCare Royalty Partners. The Loans are senior secured obligations of Relypsa and will mature on April 27, 2022, unless earlier prepaid or repaid in accordance with their terms prior to such date. The Loans bear interest at a rate of 11.5 percent per year, to be paid quarterly beginning June 15, 2016 and include an interestâ?only period of 30 months, which may be extended up to 48 months upon meeting certain conditions.
RLYP: 31.98 (-0.01)
Relypsa to Present at the Bank of America Merrill Lynch 2016 Health Care Conference
GlobeNewswire - Mon May 02, 3:15PM CDT
Relypsa, Inc. (Nasdaq:RLYP) today announced that John A. Orwin, president and chief executive officer, will present at the Bank of America Merrill Lynch 2016 Health Care Conference on May 10, 2016 at 3:00 p.m. PT.
RLYP: 31.98 (-0.01)
Galenica announces Expiration of Cash Tender Offer for Shares of Common Stock of Relypsa
GlobeNewswire - Thu Sep 01, 12:08AM CDT
Galenica Group today announced that its tender offer to purchase the outstanding shares of common stock of Relypsa, Inc., (NASDAQ: RLYP) at USD 32.00 per share, net to the seller in cash, without interest and less any applicable withholding taxes, expired at 12:00 midnight New York time, at the end of the day on Wednesday, August 31, 2016. The tender offer was effected by Galenica's indirect wholly owned subsidiary, Vifor Pharma USA Inc.
RLYP: 31.98 (-0.01)
Relypsa Announces Phase 4 Study Shows Veltassa(R) Demonstrated Similar Efficacy and Safety Whether Given With or Without Food in Patients with Hyperkalemia
GlobeNewswire - Tue Aug 30, 3:05PM CDT
Relypsa, Inc. (NASDAQ:RLYP), a biopharmaceutical company, today announced that the Phase 4 TOURMALINE study, which compared the efficacy and safety of Veltassa (patiromer) for oral suspension given with or without food for the treatment of hyperkalemia, met its primary endpoint. Results showed no statistically significant difference in the percent of patients achieving either week 3 or week 4 serum potassium in the target range (3.8 - 5.0 mEq/L) between the group taking Veltassa with food and that taking it without. Adverse events with Veltassa in this study were consistent with previous clinical trials. Data from the TOURMALINE study will be submitted for presentation at a future medical meeting and shared with the U.S. Food and Drug Administration (FDA).
RLYP: 31.98 (-0.01)
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Relypsa, Inc. (RLYP)
GlobeNewswire - Mon Aug 15, 6:00PM CDT
Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Relypsa, Inc. ("Relypsa" or the "Company"
(Nasdaq:RLYP) in the United States District Court for the Northern District of California on behalf of current stock holders of Relypsa, seeking to pursue remedies under the Securities Exchange Act of 1934 (the "Exchange Act". RLYP: 31.98 (-0.01)
Galenica commences Tender Offer for Relypsa
GlobeNewswire - Thu Aug 04, 12:08AM CDT
Galenica Group today announced that its indirect wholly owned subsidiary, Vifor Pharma USA Inc., is commencing today its previously announced tender offer for any and all outstanding shares of common stock of Relypsa, Inc. (NASDAQ: RLYP) at a price of USD 32.00 per share in cash, without interest and less applicable withholding taxes. The tender offer is being made in connection with the Agreement and Plan of Merger, dated July 20, 2016, among Galenica Ltd., Vifor Pharma USA Inc. and Relypsa, Inc.
RLYP: 31.98 (-0.01)
Biotechnology Stocks Under Review - Eleven Biotherapeutics, Relypsa, Galena Biopharma, and Amgen
PR Newswire - Mon Jun 20, 7:25AM CDT
On Friday, June 17, 2016, the NASDAQ Composite ended the trading session at 4,800.34, down 0.92%; the Dow Jones Industrial Average edged 0.33% lower, to finish at 17,675.16; and the S&P 500 closed at 2,071.22, down 0.33%. However, five out of nine sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Eleven Biotherapeutics Inc. (NASDAQ: EBIO), Relypsa Inc. (NASDAQ: RLYP), Galena Biopharma Inc. (NASDAQ: GALE), and Amgen Inc. (NASDAQ: AMGN). Learn more about these stocks by accessing their free trade alerts at:
EBIO: 4.84 (-0.05), RLYP: 31.98 (-0.01), AMGN: 169.77 (-0.36), GALE: 0.40 (unch)
Relypsa Announces New Employment Inducement Grants
GlobeNewswire - Mon Jun 06, 3:15PM CDT
Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on June 1, 2016, the compensation committee of the company's board of directors granted 2 new employees options to purchase an aggregate of 6,250 shares of the company's common stock with a per share exercise price of $19.86, the closing trading price on the grant date, and 3,125 restricted stock units. The stock options and restricted stock units were granted pursuant to the Relypsa, Inc. 2014 Employment Commencement Incentive Plan, which was approved by the company's board of directors in June 2014 under Rule 5635(c)(4) of the Nasdaq Global Select Market for equity grants to induce new employees to enter into employment with the company.
RLYP: 31.98 (-0.01)
Relypsa (RLYP) Shows Strength: Stock Moves 8.8% Higher
Zacks Equity Research - Zacks Investment Research - Mon May 30, 7:15AM CDT
Relypsa, Inc. (RLYP) shares rose almost 9% in the last trading session.
RLYP: 31.98 (-0.01), AZN: 33.31 (+0.71)
Relypsa Up on CRL for AstraZeneca Hyperkalemia Drug
Zacks Equity Research - Zacks Investment Research - Mon May 30, 6:30AM CDT
Shares of Relypsa, Inc. (RLYP) gained after AstraZeneca (AZN) received a CRL regarding its NDA for its hyperkalemia candidate, ZS-9.
RLYP: 31.98 (-0.01), PFE: 34.77 (+0.09), AZN: 33.31 (+0.71), BMY: 56.35 (-0.41)
Relypsa Submits Supplemental New Drug Application to FDA Requesting Label Changes for Veltassa Based on Phase 1 Drug-Drug Interaction Studies
GlobeNewswire - Wed May 25, 3:15PM CDT
Relypsa, Inc. (NASDAQ:RLYP), a biopharmaceutical company, today announced that the company has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) requesting label changes for Veltassa(patiromer) for oral suspension based on results of 12 Phase 1 drug-drug interaction studies in healthy volunteers.
RLYP: 31.98 (-0.01)
Data from New Analyses of Studies with Veltassa(R) Presented at 53rd European Renal Association Congress
GlobeNewswire - Sun May 22, 10:00AM CDT
Relypsa, Inc. (NASDAQ:RLYP), a biopharmaceutical company, today announced that data from new analyses of studies with Veltassa(patiromer) for oral suspension were presented at the 53 Congress of the European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) in Vienna.
RLYP: 31.98 (-0.01)
Why Under Armour, Relypsa, and HollyFrontier Slumped Today
Dan Caplinger, The Motley Fool - Motley Fool - Wed May 04, 5:33PM CDT
Image: Under Armour. Wednesday put continued pressure on the stock market, and investors appeared to focus on ongoing pressure in the energy sector and fears about global macroeconomic conditions in pushing major market benchmarks lower on the day....
UA: 38.56 (-1.19), RLYP: 31.98 (-0.01), HFC: 24.68 (+0.03)
Relypsa reports 1Q loss
Automated Insights - Wed May 04, 5:02PM CDT
REDWOOD CITY, Calif. (AP) _ Relypsa Inc. (RLYP) on Wednesday reported a loss of $54.8 million in its first quarter.
RLYP: 31.98 (-0.01)
Relypsa Reports First Quarter 2016 Financial Results
GlobeNewswire - Wed May 04, 3:07PM CDT
Relypsa Management to Host Conference Call/Webcast this Afternoon at 5:00 p.m. ET/2:00 p.m. PT
RLYP: 31.98 (-0.01)
Why Relypsa Inc.'s Shares Are Crashing 16% Today
Todd Campbell, The Motley Fool - Motley Fool - Wed May 04, 11:01AM CDT
SOURCE: RELYPSA, INC. What: After closing an offering of $150 million in senior-secured loans yesterday, shares of Relypsa are trading lower by 15.9% at 11:00 a.m. EST Wednesday morning. So what: The company has borrowed $150 million in...
RLYP: 31.98 (-0.01)
Relypsa Announces $150 Million Debt Financing
GlobeNewswire - Tue May 03, 3:15PM CDT
Relypsa, Inc. (NASDAQ:RLYP), a biopharmaceutical company, today announced the closing of $150 million in aggregate principal amount of senior secured term loans (the "Loans"
, led by funds advised by Athyrium Capital Management and joined by HealthCare Royalty Partners. The Loans are senior secured obligations of Relypsa and will mature on April 27, 2022, unless earlier prepaid or repaid in accordance with their terms prior to such date. The Loans bear interest at a rate of 11.5 percent per year, to be paid quarterly beginning June 15, 2016 and include an interestâ?only period of 30 months, which may be extended up to 48 months upon meeting certain conditions. RLYP: 31.98 (-0.01)
Relypsa to Present at the Bank of America Merrill Lynch 2016 Health Care Conference
GlobeNewswire - Mon May 02, 3:15PM CDT
Relypsa, Inc. (Nasdaq:RLYP) today announced that John A. Orwin, president and chief executive officer, will present at the Bank of America Merrill Lynch 2016 Health Care Conference on May 10, 2016 at 3:00 p.m. PT.
RLYP: 31.98 (-0.01)
(0)
(0)Scroll down for more posts ▼